A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 25 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Jul 2017 Planned number of patients changed from 516 to 564.
- 04 Jul 2017 Planned End Date changed from 1 Mar 2022 to 1 Mar 2021.